Abstract
Platelets, like neurons, contain 120- to 130- and 110-kd amyloid precursor proteins (APPs). Their ratio is reduced in AD, further reductions correlating with reduced Mini-Mental Status Examination scores [r(11) = 0.69, p < 0.05]. As statins alter APP processing, platelet APPs were analyzed in patients with AD given anticholesterol drugs for 6 weeks. APP ratios increased [t(37) = -3.888, p = 0.0004], proportionally with reduced cholesterol [r(36) = -0.45, p = 0.005]. Longer trials may reveal slowed cognitive loss, validating this index.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Alzheimer Disease / blood*
-
Alzheimer Disease / drug therapy
-
Amyloid beta-Peptides / blood*
-
Amyloid beta-Protein Precursor / blood*
-
Blood Platelets / drug effects*
-
Blood Platelets / metabolism
-
Cholesterol / blood
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Lovastatin / pharmacology*
-
Lovastatin / therapeutic use
-
Niacin / pharmacology
-
Niacin / therapeutic use
-
Pravastatin / pharmacology*
-
Pravastatin / therapeutic use
-
Protein Processing, Post-Translational / drug effects
-
Simvastatin / pharmacology*
-
Simvastatin / therapeutic use
-
Single-Blind Method
Substances
-
Amyloid beta-Peptides
-
Amyloid beta-Protein Precursor
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Niacin
-
Cholesterol
-
Lovastatin
-
Simvastatin
-
Pravastatin